Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Feasibility of cisplatin/5-fluorouracil and panitumumab in Japanese patients with squamous cell carcinoma of the head and neck.

Tahara M, Onozawa Y, Fujii H, Monden N, Yana I, Otani S, Hasegawa Y.

Jpn J Clin Oncol. 2014 Jul;44(7):661-9. doi: 10.1093/jjco/hyu063. Epub 2014 May 16.

2.

Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.

Boku N, Sugihara K, Kitagawa Y, Hatake K, Gemma A, Yamazaki N, Muro K, Hamaguchi T, Yoshino T, Yana I, Ueno H, Ohtsu A.

Jpn J Clin Oncol. 2014 Mar;44(3):214-23. doi: 10.1093/jjco/hyt196. Epub 2014 Feb 12.

3.

[Pharmacological and clinical profiles of panitumumab injection (Vectibix®)].

Matsudaira T, Asahi D, Yana I, Aboshi M.

Nihon Yakurigaku Zasshi. 2011 Jan;137(1):31-41. Review. Japanese. No abstract available.

PMID:
21233587
4.

The role of MT2-MMP in cancer progression.

Ito E, Yana I, Fujita C, Irifune A, Takeda M, Madachi A, Mori S, Hamada Y, Kawaguchi N, Matsuura N.

Biochem Biophys Res Commun. 2010 Mar 5;393(2):222-7. doi: 10.1016/j.bbrc.2010.01.105. Epub 2010 Feb 1.

PMID:
20117087
5.

Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase.

Li XY, Ota I, Yana I, Sabeh F, Weiss SJ.

Mol Biol Cell. 2008 Aug;19(8):3221-33. doi: 10.1091/mbc.E08-01-0016. Epub 2008 May 21.

6.

Establishment of an MT4-MMP-deficient mouse strain representing an efficient tracking system for MT4-MMP/MMP-17 expression in vivo using beta-galactosidase.

Rikimaru A, Komori K, Sakamoto T, Ichise H, Yoshida N, Yana I, Seiki M.

Genes Cells. 2007 Sep;12(9):1091-100.

7.

Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice.

Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, Shiomi T, Okada Y, Itoh T, Itohara S, Seiki M, Yana I.

Cancer Res. 2007 May 1;67(9):4311-9.

8.

Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells.

Yana I, Sagara H, Takaki S, Takatsu K, Nakamura K, Nakao K, Katsuki M, Taniguchi S, Aoki T, Sato H, Weiss SJ, Seiki M.

J Cell Sci. 2007 May 1;120(Pt 9):1607-14. Epub 2007 Apr 3.

9.

Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand.

Hikita A, Yana I, Wakeyama H, Nakamura M, Kadono Y, Oshima Y, Nakamura K, Seiki M, Tanaka S.

J Biol Chem. 2006 Dec 1;281(48):36846-55. Epub 2006 Oct 3.

10.
11.

Absence of mechanical allodynia and Abeta-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase.

Komori K, Nonaka T, Okada A, Kinoh H, Hayashita-Kinoh H, Yoshida N, Yana I, Seiki M.

FEBS Lett. 2004 Jan 16;557(1-3):125-8.

12.

Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils.

Matsuda A, Itoh Y, Koshikawa N, Akizawa T, Yana I, Seiki M.

J Biol Chem. 2003 Sep 19;278(38):36350-7. Epub 2003 Jul 14.

13.
14.

Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis.

Seiki M, Koshikawa N, Yana I.

Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):129-43. Review.

PMID:
12784992
15.

[Matrix metalloproteinases; the past, present, and future].

Yana I, Seiki M.

Nihon Shokakibyo Gakkai Zasshi. 2003 Feb;100(2):144-51. Review. Japanese. No abstract available.

PMID:
12649853
16.

CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain.

Mori H, Tomari T, Koshikawa N, Kajita M, Itoh Y, Sato H, Tojo H, Yana I, Seiki M.

EMBO J. 2002 Aug 1;21(15):3949-59.

17.

MT-MMPs play pivotal roles in cancer dissemination.

Yana I, Seiki M.

Clin Exp Metastasis. 2002;19(3):209-15. Review.

PMID:
12067201
18.

Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes.

Hotary KB, Yana I, Sabeh F, Li XY, Holmbeck K, Birkedal-Hansen H, Allen ED, Hiraoka N, Weiss SJ.

J Exp Med. 2002 Feb 4;195(3):295-308.

19.

Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity.

Uekita T, Itoh Y, Yana I, Ohno H, Seiki M.

J Cell Biol. 2001 Dec 24;155(7):1345-56. Epub 2001 Dec 24.

20.

Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth.

Hayashita-Kinoh H, Kinoh H, Okada A, Komori K, Itoh Y, Chiba T, Kajita M, Yana I, Seiki M.

Cell Growth Differ. 2001 Nov;12(11):573-80.

21.
22.
23.

A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma.

Ohnishi T, Tomita N, Monden T, Ohue M, Yana I, Takami K, Yamamoto H, Yagyu T, Kikkawa N, Shimano T, Monden M.

Br J Cancer. 1997;75(3):341-7.

24.

An EcoRI RFLP in human APC gene.

Kurahashi H, Takami K, Yana I, Akagi K, Okada S, Nishisho I.

Jpn J Hum Genet. 1995 Dec;40(4):339-41.

PMID:
8851769
25.

Frequent loss of heterozygosity at telomeric loci on 22q in sporadic colorectal cancers.

Yana I, Kurahashi H, Nakamori S, Kameyama M, Nakamura T, Takami M, Mori T, Takai S, Nishisho I.

Int J Cancer. 1995 Jan 17;60(2):174-7.

PMID:
7829211
26.

Multistep carcinogenesis in colorectal cancers.

Takami K, Yana I, Kurahashi H, Nishisho I.

Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6. Review.

PMID:
8629105
27.

Clinicopathological findings and p53 expression of thyroid cancer in children.

Kobayashi T, Nakanishi H, Yana I, Nishisho I, Itoh Y, Wakasugi E, Takeda T, Mori T.

Surg Today. 1995;25(3):217-21.

PMID:
7640449
28.

A frequent alteration of p53 gene in carcinoma in adenoma of colon.

Ohue M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami K, Yana I, Ohnishi T, Enomoto T, Inoue M, et al.

Cancer Res. 1994 Sep 1;54(17):4798-804.

29.

Refined mapping of eight cosmid markers on human chromosome 22.

Kurahashi H, Akagi K, Yana I, Melot T, Delattre O, Thomas G, Okada S, Takai S, Nishisho I.

Jpn J Hum Genet. 1994 Jun;39(2):243-8.

PMID:
7916219
30.

p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, Miya A, Mori T, Nishisho I, Takai S.

Jpn J Cancer Res. 1992 Dec;83(12):1293-8.

31.

Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.

Yana I, Nakamura T, Shin E, Karakawa K, Kurahashi H, Kurita Y, Kobayashi T, Mori T, Nishisho I, Takai S.

Jpn J Cancer Res. 1992 Nov;83(11):1113-6.

Supplemental Content

Support Center